Achilles Therapeutics Plc (ACHL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 236,931 | 266,319 | 281,875 | 299,317 | 159,262 |
| TOTAL | $259,049 | $284,749 | $298,276 | $320,402 | $173,320 |
| Non-Current Assets | |||||
| PPE Net | 18,376 | 17,743 | 16,378 | 16,611 | 15,479 |
| Other Non-Current Assets | 14,765 | 14,614 | 15,345 | 16,477 | 17,304 |
| TOTAL | $33,141 | $32,357 | $31,723 | $33,088 | $32,783 |
| Total Assets | $292,190 | $317,106 | $329,999 | $353,490 | $206,103 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,036 | 3,722 | 2,460 | 6,055 | 1,787 |
| Accrued Expenses | 9,131 | 10,906 | 8,472 | 7,879 | 8,646 |
| TOTAL | $17,852 | $19,110 | $15,366 | $18,613 | $15,062 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 671 | 691 | 643 | 659 | 659 |
| TOTAL | $7,883 | $8,468 | $9,524 | $10,903 | $11,988 |
| Total Liabilities | $25,735 | $27,578 | $24,890 | $29,516 | $27,050 |
| Shareholders' Equity | |||||
| Common Shares | 54 | 54 | 54 | 54 | 6 |
| Retained earnings | -136,466 | -119,111 | -100,881 | -87,933 | -71,777 |
| Other shareholders' equity | -913 | 6,764 | 5,878 | 13,588 | 14,385 |
| TOTAL | $266,455 | $289,528 | $305,109 | $323,974 | $179,053 |
| Total Liabilities And Equity | $292,190 | $317,106 | $329,999 | $353,490 | $206,103 |